Omada Health released FY2024 Q2 earnings on August 8, 2025 (EST), with actual revenue of USD 41.21 M and EPS of USD -1.3978

Brief Summary

Omada Health reported a Q2 2024 revenue of $41.21 million and an EPS of -$1.3978, indicating continued financial challenges.

Impact of The News

Financial Performance Analysis

• Revenue: Omada Health’s revenue for Q2 2024 was $41.21 million. This figure alone does not provide a clear indication of whether it beat or missed market expectations since no benchmark or prior comparison is available from the given data.
• Earnings Per Share (EPS): The EPS was -$1.3978, indicating a loss, which aligns with the reported net profit loss of $10.692 million, reflecting the company’s struggle to achieve profitability during this period.

Peer Comparison

• Compared to the information available from other companies, such as Bajie Shenzhou’s revenue increase and narrowing losses , Omada Health’s continued losses may suggest it is not on par with peers who are showing signs of financial recovery or growth.

Business Status and Trends

• Current Business Status: The significant EPS loss suggests that Omada Health is still in a challenging financial situation. The revenue figure reflects operational activity but not profitability.
• Potential Trends: Given the financial loss, Omada Health may need to explore strategies to enhance revenue growth while controlling costs. It could be facing competitive pressures or market challenges that hinder profitability.
• Market Expectations: Without explicit market expectations or analyst forecasts, it is difficult to determine how this performance aligns with investor expectations. However, the negative EPS might influence investor sentiment negatively unless offset by strategic business improvements.